The company is testing a five-protein panel in longitudinal samples to see if it could help with early detection and prediction of progression in Alzheimer's.
Caprion will use its mass spec platform to measure Alzheimer's-linked proteins in the CSF of more than 200 patients and controls over three or more years.
The company expects its purchase of ImmuneHealth's immune monitoring laboratory will help it win business for clinical work requiring fresh sample analysis.
Caprion said it will use the lab to expand its immune monitoring offering and strengthen its business partnerships and research collaborations in Europe.
Under new ownership after being acquired by GHO Capital, the company will consider expanding its business through acquisitions and moving into new geographies.
GHO, a London-based investment firm, purchased the company for an undisclosed amount from Chicago Growth Partners, Caprion's majority shareholder since 2012.
The study, which looked at markers of immune senescence in older patients, suggests the platform could be useful in diagnostic and companion diagnostic work.
The company hopes to launch the test sometime this year after completing CLIA certification of its clinical laboratory and securing reimbursement.
The agreement gives Caprion, which did significant development work on the test, exclusive rights to market and commercialize Xpresys Lung inCanada.
Caprion will use its discovery and targeted mass spec platforms to analyze roughly 400 samples from the UK Collaborative Trial for Ovarian Cancer Screening.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.